参考资料（上下滑动查看全部）：

[1]SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ALSO THE CURATIVE AND SAFE TREATMENT FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN THE ERA OF TARGETED THERAPY EHA2023 P1302

[2]减低强度预处理并更换供者二次异基因造血干细胞移植后复发恶性血液病44例临床研究，《中国血液学杂志》2023年6月

[3]Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Hematological Malignancies: Comparison of Different Conditioning Regimens APBMT2023 P49

[4]Zhihui Li，Keyan Yang，et,al.CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results, Frontiers in Oncology,2022,10

[5]CD7 Chimeric Antigen Receptor T-Cell Therapy Bridging to Allogeneic Hematopoietic Stem Cell Transplantation Remarkably Improved Long-Term Disease-Free Survival in Refractory/Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma ASH2023 P239

[6]Allogeneic Hematopoietic Stem Cell Transplantation in Refractory/Relapsed Acute Myeloid Leukemia: Outcomes and Risk Factors for Prognosis APBMT 2023 P41

[7]Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Hematological Malignancies: Comparison of Different Conditioning Regimens APBMT 2023 P49

[8]Profiles of Germline Predisposition Gene Variants in Hematologic Disorders and Its Impact on Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation ASH2022 P3425

[9]A real-world study of lenalidomide combined with low-dose venecla in maintenance therapy after allogeneic hematopoietic stem cell transplantation for recurrent and refractory hematological malignancies EBMT 2023 P268

[10]Maintenance Therapy with Trametinib after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with RAS Mutated Hematologic Malignancies APBMT2023 P67